Trade CYTK stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Cytokinetics, Incorporated (CYTK) is trading at US$69.31, down 4.33% today as of Sep 15, 16:00 EDT. The company has a market capitalisation of US$10.68B. Over the past 52 weeks, CYTK has traded between US$47.22 and US$88.31. On Syfe you can trade CYTK with $0 commission and add it to your watchlist.
| Previous close | US$72.45 |
|---|---|
| Market cap | US$10.68B |
| 52-week range | US$47.22 – US$88.31 |
| Volume | 2.39M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Cytokinetics, Incorporated
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Year: 2004
Cytokinetics, Incorporated (CYTK) stock is trading at US$69.31, -4.33% from the previous close of US$72.45.
The market cap for Cytokinetics, Incorporated (CYTK) stock is approximately US$10.68B.
The 52-week high for Cytokinetics, Incorporated (CYTK) stock is US$88.31.
The 52-week low for Cytokinetics, Incorporated (CYTK) stock is US$47.22.
Cytokinetics, Incorporated (CYTK) does not currently pay a dividend.
Stay on top of CYTK
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
